Is Elective Cancer Surgery Safe During the COVID-19 Pandemic?
Adult
Aged
Aged, 80 and over
Betacoronavirus
COVID-19
Coronavirus Infections
/ diagnosis
Elective Surgical Procedures
Female
Follow-Up Studies
Humans
Incidence
Male
Middle Aged
Neoplasms
/ surgery
Pandemics
/ prevention & control
Patient Safety
Pneumonia, Viral
/ diagnosis
Postoperative Complications
/ diagnosis
Retrospective Studies
Risk Factors
SARS-CoV-2
United Kingdom
Journal
World journal of surgery
ISSN: 1432-2323
Titre abrégé: World J Surg
Pays: United States
ID NLM: 7704052
Informations de publication
Date de publication:
10 2020
10 2020
Historique:
accepted:
08
07
2020
pubmed:
9
8
2020
medline:
10
9
2020
entrez:
9
8
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has resulted in a significant decrease in the number of elective cancer operations performed. Cancer patients are felt to be a high-risk group for COVID-19, and therefore, concerns have been raised regarding the safety of operating during this time; however, the potential risk of cancer progression if untreated must also be considered. The aim of this study was therefore to identify the incidence of COVID-19 post-operatively in patients undergoing elective cancer surgery of all types. Data were collected on all patients who had an elective therapeutic cancer operation in a single large district general hospital, where standard COVID-19 precautions were in place, between 01/02/2020 and 27/4/2020, Follow-up was for a minimum of 2 weeks post-discharge. The primary outcome was the incidence of COVID-19 during the follow-up period. A total of 621 elective cancer surgeries, from a range of specialities, were performed during the study period, with 55% (n = 341) being done as day cases. None of the patients were positive for COVID-19 post-operatively using reverse transcriptase polymerase chain reaction testing. The risk of COVID-19 following elective cancer surgery in this group of high-risk patients appears to be minimal in this study. With further precautions being introduced to reduce the risk of transmission of COVID-19, an increase in the rate of elective cancer surgery should be a current priority for all hospitals where possible.
Sections du résumé
BACKGROUND
The COVID-19 pandemic has resulted in a significant decrease in the number of elective cancer operations performed. Cancer patients are felt to be a high-risk group for COVID-19, and therefore, concerns have been raised regarding the safety of operating during this time; however, the potential risk of cancer progression if untreated must also be considered. The aim of this study was therefore to identify the incidence of COVID-19 post-operatively in patients undergoing elective cancer surgery of all types.
METHODS
Data were collected on all patients who had an elective therapeutic cancer operation in a single large district general hospital, where standard COVID-19 precautions were in place, between 01/02/2020 and 27/4/2020, Follow-up was for a minimum of 2 weeks post-discharge. The primary outcome was the incidence of COVID-19 during the follow-up period.
RESULTS
A total of 621 elective cancer surgeries, from a range of specialities, were performed during the study period, with 55% (n = 341) being done as day cases. None of the patients were positive for COVID-19 post-operatively using reverse transcriptase polymerase chain reaction testing.
CONCLUSIONS
The risk of COVID-19 following elective cancer surgery in this group of high-risk patients appears to be minimal in this study. With further precautions being introduced to reduce the risk of transmission of COVID-19, an increase in the rate of elective cancer surgery should be a current priority for all hospitals where possible.
Identifiants
pubmed: 32766957
doi: 10.1007/s00268-020-05720-x
pii: 10.1007/s00268-020-05720-x
pmc: PMC7410357
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3207-3211Références
Oncologist. 2020 Jun;25(6):e936-e945
pubmed: 32243668
Lancet Infect Dis. 2020 Aug;20(8):911-919
pubmed: 32353347
Ann Plast Surg. 2020 Aug;85(2S Suppl 2):S155-S160
pubmed: 32358230
Br J Surg. 2020 Jun;107(7):785-787
pubmed: 32191340
BMJ. 2020 Mar 18;368:m1106
pubmed: 32188602
Eur J Radiol. 2020 May;126:108961
pubmed: 32229322
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Lancet. 2020 Mar 28;395(10229):1015-1018
pubmed: 32197103
Ann Intern Med. 2020 Jun 2;172(11):756-758
pubmed: 32219410
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
Ann Surg. 2020 Jul;272(1):e20-e21
pubmed: 32301804
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622
Am J Surg. 2020 Jun;219(6):900-902
pubmed: 32312477
BMJ. 2020 Apr 1;369:m1327
pubmed: 32238354